PDZK1IP1 and hepatocellular carcinoma: The mean DFS in HCC patients with low MAP17 expression was 50.19 months (95% CI, 42.27-58.11), compared with 34.91 months (95% CI, 29.29-40.53) in patients with high MAP17 expression (p = 0.004, Figure 1B).